Haemodynamically Derived Pulmonary Artery Pulsatility Index Predicts Mortality in Pulmonary Arterial Hypertension.


Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
May 2019
Historique:
received: 26 09 2017
revised: 21 02 2018
accepted: 02 04 2018
pubmed: 12 5 2018
medline: 13 4 2019
entrez: 12 5 2018
Statut: ppublish

Résumé

Pulmonary artery (PA) pulsitility index (PAPi) is a novel haemodynamic index shown to predict right ventricular failure in acute inferior myocardial infarction and post left ventricular assist device surgery. We hypothesised that PAPi calculated as [PA systolic pressure - PA diastolic pressure]/right atrial pressure (RAP) would be associated with mortality in the National Institutes of Health Registry for Primary Pulmonary Hypertension (NIH-RPPH). The impact of PAPi, the Pulmonary Hypertension Connection (PHC) risk score, right ventricular stroke work, pulmonary artery capacitance (PAC), other haemodynamic indices, and demographic characteristics was evaluated in 272 NIH-RPPH patients using multivariable Cox proportional hazards (CPH) regression and receiver operating characteristic (ROC) analysis. In the 272 patients (median age 37.7+/-15.9years, 63% female), the median PAPi was 5.8 (IQR 3.7-9.2). During 5years of follow-up, 51.8% of the patients died. Survival was markedly lower (32.8% during the first 3years) in PAPi quartile 1 compared with the remaining patients (58.5% over 3years in quartiles 2-4; p<0.0001). The best multivariable CPH survival model included PAPi, the PHC-Risk score, PAC, and body mass index (BMI). In this model, the adjusted hazard ratio for death with increasing PAPi was 0.946 (95% CI 0.905-0.989). The independent ROC areas for 5-year survival based on bivariable logistic regression for PAPi, BMI, PHC Risk, and PAC were 0.63, 0.62, 0.64, and 0.65, respectively (p<0.01). The ROC area for 5-year survival for the multivariable logistic model with all four covariates was 0.77 (p<0.0001). Pulmonary artery pulsatility index was independently associated with survival in PAH, highlighting the utility of PAPi in combination with other key measures for risk stratification in this population.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary artery (PA) pulsitility index (PAPi) is a novel haemodynamic index shown to predict right ventricular failure in acute inferior myocardial infarction and post left ventricular assist device surgery. We hypothesised that PAPi calculated as [PA systolic pressure - PA diastolic pressure]/right atrial pressure (RAP) would be associated with mortality in the National Institutes of Health Registry for Primary Pulmonary Hypertension (NIH-RPPH).
METHODS METHODS
The impact of PAPi, the Pulmonary Hypertension Connection (PHC) risk score, right ventricular stroke work, pulmonary artery capacitance (PAC), other haemodynamic indices, and demographic characteristics was evaluated in 272 NIH-RPPH patients using multivariable Cox proportional hazards (CPH) regression and receiver operating characteristic (ROC) analysis.
RESULTS RESULTS
In the 272 patients (median age 37.7+/-15.9years, 63% female), the median PAPi was 5.8 (IQR 3.7-9.2). During 5years of follow-up, 51.8% of the patients died. Survival was markedly lower (32.8% during the first 3years) in PAPi quartile 1 compared with the remaining patients (58.5% over 3years in quartiles 2-4; p<0.0001). The best multivariable CPH survival model included PAPi, the PHC-Risk score, PAC, and body mass index (BMI). In this model, the adjusted hazard ratio for death with increasing PAPi was 0.946 (95% CI 0.905-0.989). The independent ROC areas for 5-year survival based on bivariable logistic regression for PAPi, BMI, PHC Risk, and PAC were 0.63, 0.62, 0.64, and 0.65, respectively (p<0.01). The ROC area for 5-year survival for the multivariable logistic model with all four covariates was 0.77 (p<0.0001).
CONCLUSIONS CONCLUSIONS
Pulmonary artery pulsatility index was independently associated with survival in PAH, highlighting the utility of PAPi in combination with other key measures for risk stratification in this population.

Identifiants

pubmed: 29748060
pii: S1443-9506(18)30451-7
doi: 10.1016/j.hlc.2018.04.280
pmc: PMC7175917
mid: NIHMS1067359
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

752-760

Subventions

Organisme : NHLBI NIH HHS
ID : K01 HL142848
Pays : United States
Organisme : NHLBI NIH HHS
ID : R03 HL135463
Pays : United States

Informations de copyright

Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Références

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):593-600
pubmed: 21954053
J Heart Lung Transplant. 2016 Jan;35(1):67-73
pubmed: 26212656
J Card Fail. 2016 Feb;22(2):110-6
pubmed: 26564619
Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6
pubmed: 22798320
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33
pubmed: 24355638
Circulation. 2010 Jul 13;122(2):164-72
pubmed: 20585012
J Am Coll Cardiol. 2012 Sep 25;60(13):1202-3
pubmed: 22995025
Chest. 2012 Mar;141(3):642-650
pubmed: 21885728
J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9
pubmed: 22133851
J Am Coll Cardiol. 2002 Aug 21;40(4):780-8
pubmed: 12204511
N Engl J Med. 2004 Oct 14;351(16):1655-65
pubmed: 15483284
J Physiol. 1914 Sep 8;48(5):357-79
pubmed: 16993262
Am J Respir Crit Care Med. 2012 Sep 1;186(5):396-7
pubmed: 22942342
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9
pubmed: 24355642
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41
pubmed: 24355639
Ann Thorac Surg. 2006 Sep;82(3):989-95
pubmed: 16928521
Cardiovasc Res. 1971 Jan;5(1):1-9
pubmed: 5544955
J Physiol. 1912 Dec 9;45(5):307-17
pubmed: 16993158
Ann Intern Med. 1991 Sep 1;115(5):343-9
pubmed: 1863023
Ann Am Thorac Soc. 2016 Feb;13(2):276-84
pubmed: 26848601
Eur Respir Rev. 2013 Dec;22(130):487-94
pubmed: 24293464
Am J Physiol. 1994 Jul;267(1 Pt 2):H155-65
pubmed: 8048580
Circulation. 2009 Sep 15;120(11):992-1007
pubmed: 19752350
Circulation. 2008 Mar 18;117(11):1436-48
pubmed: 18347220
Eur Respir Rev. 2011 Dec;20(122):243-53
pubmed: 22130817
Ann Med. 2001 May;33(4):236-41
pubmed: 11405544
Respir Med. 2007 Dec;101(12):2495-501
pubmed: 17719764
Circulation. 1994 Apr;89(4):1733-44
pubmed: 8149539
Circulation. 2010 Jul 13;122(2):156-63
pubmed: 20585011
Chest. 2011 Jun;139(6):1299-1309
pubmed: 21148241
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1774-85
pubmed: 12763744
Circ Res. 1974 Apr;34(4):498-504
pubmed: 4826926

Auteurs

Sula Mazimba (S)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA. Electronic address: SM8SD@hscmail.mcc.virginia.edu.

Timothy S Welch (TS)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Hunter Mwansa (H)

St Vincent Charity Medical Center, Case Western Reserve University, Cleveland, OH, USA.

Khadijah K Breathett (KK)

Division of Cardiovascular Medicine, University of Arizona, Tucson, AZ, USA.

Jamie L W Kennedy (JLW)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Andrew D Mihalek (AD)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA.

William C Harding (WC)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Manu M Mysore (MM)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

David X Zhuo (DX)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Kenneth C Bilchick (KC)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH